Drug Profile
Research programme: PEGylated recombinant interleukin-11 protein - Helixmith
Alternative Names: NL 002 1; PEG-VM 501Latest Information Update: 08 Aug 2019
Price :
$50
*
At a glance
- Originator ViroMed Co Ltd
- Developer ViroMed
- Class Chemoprotectants; Interleukins; Recombinant proteins
- Mechanism of Action Haematopoiesis stimulants; Interleukin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Thrombocytopenia
Highest Development Phases
- No development reported Thrombocytopenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombocytopenia(Chemotherapy-induced) in South Korea (SC, Injection)
- 27 May 2013 PEG-VM501 is available for licensing worldwide (excluding China) once it enters clinical development. http://viromed.co.kr/
- 01 May 2013 Preclinical development is ongoing in South Korea